Using published, institutional data to evaluate the cost effectiveness of DVT prophylaxis

Formulary

Volumn 31, Issue 12, 1996, Pages 1203-1210

  Wade, William E ^a   Taylor, A Thomas ^a,b   Spruill, William J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008888251     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hoek JA, Nurmohamed MT, Hamehynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight hepari-noid. Throm Haemost 1992;67:28-32.
2. Lassen MR, Bonis LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: Comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-8.
3. Turpie AG, Leclerc JR. Prophylaxis of venous thromboembolism. In: Leclerc JR, ed. Venous Thromboembolic Disorders. Philadelphia: Lea & Febiger, 1991:303-45.
4. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990;263:2313-7.
5. Sorensen JV, Borris LC, Lassen MR. Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis-influence of prophylaxis with low molecular weight heparin. Throm Res 1990;59:131-8.
6. Biesaw NE, Comerota AJ, Groth HE, et al. Dihydroergotamine/heparin in the prevention of deep-vein thromboses after total hip replacement: a controlled, prospective, randomized multicenter trial. J Bone Joint Surg 1988; 70A:2-10.
7. Silver D. An overview of venous thromboembolism prophylaxis. Am J Surg 1991;161:537-40.
8. Stulberg B, Insall J, Williams G et al. Deep-vein thrombosis following total knee replacement: An analysis of six hundred and thirfy-eight arthroplasties. J Bone Joint Surg 1984;66A:194-201.
9. Stringer M, Steadman C, Hedges A, et al. Deep-vein thrombosis after elective knee surgery: An incidence study in 312 patients. J Bone Joint Surg 1989; 71B:492-7.
10. Hull R, Delmore T, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and r thigh vein thrombosis in patients undergoing elective knee surgery. Throm Res 1979;16:37-45.
11. Oster G, Tuden RL, Colditz A. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987;257:203-8.
12. National Institutes of Health Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986;256:744-9.
13. Bell RW, Simon TL. Current status of pulmonary thromboembolic disease: Pathophysiology, diagnosis, prevention and treatment. Am Heart J 1982;103: 239-62.
14. Hull RD, Hirsh J. Advances and controversies in the diagnosis, prevention, and treatment of venous thromboembolism. Prog Hematol 1981;12:73-123.
15. Coon WW. The spectrum of pulmonary embolism Arch Surg 1976;111:398-402.
16. Goldhaber SZ. Strategies for diagnosis. In: Goldhaber SZ, ed. Pulmonary embolism and deep venous thrombosis. Philadelphia, PA: WB Saunders Co, 1985;79-97.
17. Paiement GD, Wessinger SJ, Harris WH. Survey of prophylaxis against venous thrombosis in adults undergoing hip surgery. Clin Orthop 1987;223:188-93.
18. Clagett GP, Salzman EW, Wheeler HB, et al. Prevention of venous thromboembolism. Chest 1992;102(Suppl):391S-407S.
19. Harris WH, Salzman EW, Athanasoulis C, et al. Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg Am 1974;56:1552-62.
20. Barre J, Pfister G, Patron G, et al. Comparison of the efficacy and safety of Kabi 2165 and standard heparin in the prevention of deep vein thrombosis following total hip arthroplasty. J Mal Vasc 1987;12:90-5.
21. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Throm Haemost 1988;60:407-10.
22. Deehavanne M, Ville D, Berruer M, et al. Randomized trial of low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemost 1989;1:5-12.
23. Eriksson BI, Eriksson E, Wadenvik H, et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991; 73A:484-9.
24. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. Ann Intern Med 1991;114:545-51.
25. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: Randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543-8.
26. Colwell CW, Jolla LA, Spiro TE, et al. Use of enoxaparin, a low molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994; 76A:3-14
27. Hull R, Raskob G, Rosenblood D, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deepvein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
28. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism (VTE) after knee arthroplasty: A randomized double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to warfarin. Blood 1994;84(Suppl 1):246a.
29. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg 1994;765A:1174-85.
30. Spiro T, Fritzgerald R, Trowbridge A, et al. Enoxaparin, a low molecular weight heparin, and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood 1994;84(Suppl 1):245a.
31. Clagett CP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108:312S-29S.
32. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thrornboembolism: A randomized trial. World J Surg 1996;20:521-6.
33. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrmobosis. Thomb Haemost 1994;72:191-7.
34. Bakst A. Pharmacoeconomics and the formulary decision-making process. Hosp Formul 1995;30:42-50.
35. Prandoni P, Lensing AWA, Buller HR, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med 1993;327:1128-33.
36. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Infern Med 1993;119:1105-12.
37. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
38. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;150:1083-90.
39. Gallus AS. Venous thromboembolism: incident and clinical risk factors. In: Madden JL, Hume M, eds. Venous thromboembolism: Prevention and treatment. East Norwalk, CT: Appleton-Century-Crofts, 1976:1-32.
40. Hyers TN, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(Suppl): 335S-50S.
41. Lensing AWA, Prins MH, Davidson BL, et al. Treatment of deep vein thrombosis with low molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.